Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Braidwell, LP on the matter. Braidwell, LP announced the consummation of an additional investment in Nevro Corp. (NYSE: NVRO), consisting of a six-year, $200,000,000 senior...
You must be a Standard 1 Year member to access this content.
Goodwin advised Pathology Watch on the sale to Sonic Healthcare. Sonic Healthcare acquired Utah-based medical-tech provider Pathology Watch for US$150 million in what the Australian company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Advanced Biologics in its merger with Isto Biologics. Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous...
You must be a Standard 1 Year member to access this content.
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to SunMed, and Alston & Bird is serving as legal counsel to Avanos. SunMed announced it has entered into...
You must be a Standard 1 Year member to access this content.
Goodwin advised Akero Therapeutics on the offering, and Cooley advised the underwriter involved. Akero Therapeutics (Nasdaq: AKRO) announced the closing of its underwritten registered direct offering...
You must be a Standard 1 Year member to access this content.
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised CathWorks on the deal. CathWorks announced its acquisition option agreement and co-promotion agreement with Medtronic (NYSE: MDT). Under the acquisition option agreement, Medtronic will...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Navitor Pharmaceuticals on the deal. Privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies...
You must be a Standard 1 Year member to access this content.
